45 related articles for article (PubMed ID: 9054874)
1. Tracing the Evolution of Prostate Brachytherapy in the 20th Century.
Schaulin MS; Delouya G; Zwahlen D; Taussky D
Oncology; 2024; 102(3):283-290. PubMed ID: 37806307
[TBL] [Abstract][Full Text] [Related]
2. Re: Antibiotic resistance in patients undergoing serial prostate biopsies: risk factors and impact on clinical outcomes.
Clark CB; Raman JD
Can J Urol; 2024 Feb; 31(1):11775-11776. PubMed ID: 38401256
[No Abstract] [Full Text] [Related]
3. Development and internal validation of multivariable prediction models for biochemical failure after MRI-guided focal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer.
Willigenburg T; van Son MJ; van de Pol SMG; Eppinga WSC; Lagendijk JJW; de Boer HCJ; Moerland MA; van der Voort van Zyp JRN; Peters M
Clin Transl Radiat Oncol; 2021 Sep; 30():7-14. PubMed ID: 34278009
[TBL] [Abstract][Full Text] [Related]
4. Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma.
Reynolds HM; Parameswaran BK; Finnegan ME; Roettger D; Lau E; Kron T; Shaw M; Chander S; Siva S
PLoS One; 2018; 13(8):e0202387. PubMed ID: 30114235
[TBL] [Abstract][Full Text] [Related]
5. Surveillance after prostate focal therapy.
Tay KJ; Amin MB; Ghai S; Jimenez RE; Kench JG; Klotz L; Montironi R; Muto S; Rastinehad AR; Turkbey B; Villers A; Polascik TJ
World J Urol; 2019 Mar; 37(3):397-407. PubMed ID: 29948045
[TBL] [Abstract][Full Text] [Related]
6. Preliminary safety and efficacy results with robotic high-intensity focused ultrasound : A single center Indian experience.
Mishra S; Sharma R; Garg CP; Muthu V; Ganpule A; Sabnis RB; Desai MR
Indian J Urol; 2011 Jul; 27(3):331-6. PubMed ID: 22022055
[TBL] [Abstract][Full Text] [Related]
7. Advances in brachytherapy.
Grimm P; Sylvester J
Rev Urol; 2004; 6 Suppl 4(Suppl 4):S37-48. PubMed ID: 16985869
[TBL] [Abstract][Full Text] [Related]
8. 70 Gy or more: which dose for which prostate cancer?
Ganswindt U; Paulsen F; Anastasiadis AG; Stenzl A; Bamberg M; Belka C
J Cancer Res Clin Oncol; 2005 Jul; 131(7):407-19. PubMed ID: 15887028
[TBL] [Abstract][Full Text] [Related]
9. Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer.
Crook J; Lukka H; Klotz L; Bestic N; Johnston M;
CMAJ; 2001 Apr; 164(7):975-81. PubMed ID: 11314451
[TBL] [Abstract][Full Text] [Related]
10. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma.
Ragde H; Elgamal AA; Snow PB; Brandt J; Bartolucci AA; Nadir BS; Korb LJ
Cancer; 1998 Sep; 83(5):989-1001. PubMed ID: 9731904
[TBL] [Abstract][Full Text] [Related]
11. [Review on the effectiveness of prostate cancer brachytherapy].
Inciūra A; Jarusevicus L; Vaiciūnas K; Juozaityte E
Medicina (Kaunas); 2009; 45(8):660-71. PubMed ID: 19773626
[TBL] [Abstract][Full Text] [Related]
12. Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer.
Prestidge BR; Hoak DC; Grimm PD; Ragde H; Cavanagh W; Blasko JC
Int J Radiat Oncol Biol Phys; 1997 Jan; 37(1):31-9. PubMed ID: 9054874
[TBL] [Abstract][Full Text] [Related]
13. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
14. Isotope selection for patients undergoing prostate brachytherapy.
Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S
Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561
[TBL] [Abstract][Full Text] [Related]
15. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
